52 related articles for article (PubMed ID: 9657622)
1. Blood Pressure Lowering in Patients with Left Ventricular Hypertrophy - Navigating between Scylla and Charybdis.
Schoenenberger-Berzins R; Messerli FH
J Pharmacol Exp Ther; 2024 Jun; 390(1):1-3. PubMed ID: 38906565
[No Abstract] [Full Text] [Related]
2. Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: A network meta-analysis of randomized controlled trials.
Chen JS; Pei Y; Li CE; Li YN; Wang QY; Yu J
J Clin Hypertens (Greenwich); 2020 Dec; 22(12):2175-2183. PubMed ID: 33190366
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive therapy and sudden cardiac death, should we expect the unexpected?
Sanidas E; Malliaras K; Papadopoulos D; Velliou M; Tsakalis K; Zerva K; Barbetseas J
J Hum Hypertens; 2020 May; 34(5):339-345. PubMed ID: 31937855
[TBL] [Abstract][Full Text] [Related]
4. Neurohormonal intervention to reduce sudden cardiac death in heart failure: what is the optimal pharmacologic strategy?
Squire I
Heart Fail Rev; 2004 Oct; 9(4):337-45; discussion 347-51. PubMed ID: 15886979
[TBL] [Abstract][Full Text] [Related]
5. Long-term improvement of QT dispersion is unaffected by short-term changes in blood pressure during treatment of systemic hypertension with enalapril.
Seara FJ; Juanatey JR; Sande JL; Veloso PR; Reino AP; Román AV; Cerrato JC; Peña MG
Ann Noninvasive Electrocardiol; 2003 Jan; 8(1):47-54. PubMed ID: 12848813
[TBL] [Abstract][Full Text] [Related]
6. Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy.
Liebson PR; Serry RD
Curr Hypertens Rep; 2000 Jun; 2(3):260-70. PubMed ID: 10981159
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
Dahlöf B
Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension.
Pittrow DB; Antlsperger A; Welzel D; Wambach G; Schardt W; Weidinger G
Cardiovasc Drugs Ther; 1997 Nov; 11(5):619-27. PubMed ID: 9493699
[TBL] [Abstract][Full Text] [Related]
10. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
[TBL] [Abstract][Full Text] [Related]
11. Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.
Shohat J; Wittenberg C; Erman A; Rosenfeld J; Boner G
Scand J Urol Nephrol; 1999 Feb; 33(1):57-62. PubMed ID: 10100366
[TBL] [Abstract][Full Text] [Related]
12. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
13. Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries.
Thürmann PA; Stephens N; Heagerty AM; Kenedi P; Weidinger G; Rietbrock N
Hypertension; 1996 Sep; 28(3):450-6. PubMed ID: 8794832
[TBL] [Abstract][Full Text] [Related]
14. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity.
Manolis AJ; Beldekos D; Handanis S; Haralabidis G; Hatzissavas J; Foussas S; Cokkinos DV; Bresnahan M; Gavras I; Gavras H
Am J Hypertens; 1998 Jun; 11(6 Pt 1):640-8. PubMed ID: 9657622
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
